Markets
Leaderboard
Will EXO-CD24 (the nasal spray against Covid developed in Israel) enter phase II or III clinical trials in Brazil in 2021? No: real money 91%, play money 63% Yes: real money 9%, play money 37% Volume: real money 124.29198346, play money 3424.3 Bettors: real money 3, play money 10 Categories: Science, Transmissible Diseases, Covid-19 (Coronavirus), Treatments Related markets Antarctic sea ice minimum to decrease in 2027? (ID: 235045) Volume: real 500.10026694, play 50000 Bettors: real 4, play 0 Leading (real money): Antarctic sea ice minimum to decrease in 2027? 81% Leading (play money): Antarctic sea ice minimum to decrease in 2027? 81% Nipah virus declared a public health emergency by the WHO in 2026? (ID: 233776) Volume: real 100.18015496, play 14933.4347 Bettors: real 4, play 3 Leading (real money): Nipah virus declared a public health emergency by the WHO in 2026? 11% Leading (play money): Nipah virus declared a public health emergency by the WHO in 2026? 6%

Will EXO-CD24 (the nasal spray against Covid developed in Israel) enter phase II or III clinical trials in Brazil in 2021?

Market Rules

Tel Aviv’s Ichilov Medical Center has released a statement to the press informing the results of a phase I trial with its new nasal spray drug, EXO-CD24. The drug was developed to modulate the immune system and might act over the cytokine storm caused by COVID-19. The statement says 29 of 30 patients were "cured", despite not releasing any data about them at the time. Even so, Brazil's President Jair Bolsonaro is trying to convince Brazil's national health agency (ANVISA) to authorize phase II/III clinical trials and emergency approval of the drug in the country.

If ANVISA approves clinical trials with EXO-CD24 in Brazil before December 31st, 2021, this market will be resolved as "Yes"

Related Markets